The pharmacokinetic parameters of verapamil were measured after an oral (9 mg/kg) or intravenous (3 mg/kg) administration of verapamil to rats in the presence and absence of atorvastatin
Unlike other calcium antagonists, detailed pharmacokinetic data are available for verapamil
Verapamil is widely used in the treatment of supraventricular tachyarrhythmias as well as for hypertension and control of symptoms in angina pectoris
Verapamil Pharmacokinetics Absorption Class IV antiarrhythmic
Following intravenous infusion in man, verapamil is eliminated bi-exponentially, with a rapid early distribution phase (half-life about 4 minutes) and a slower terminal elimination phase (half-life 2 to 5 hours)
and oral administration and during chronic treatment
7 to 4
The plasma clearance of both The aim of this study was to report the effect of diabetes mellitus on the pharmacokinetics of verapamil in a route-dependent manner
Plasma concentrations of verapamil and its metabolite, norverapamil, were measured after oral (10 mg/kg) or intravenous (1 mg/kg) administration
; 10 mg/kg) or intravenous (i
Disappearance kinetic characteristics of verapamil were determined in 9 patients after a single intravenous dose
Utilizing a stereospecific high-performance liquid chromatographic (HPLC) assay, the enantiomeric disposition of verapamil is reported after intravenous (1
Verapamil hydrochloride is a calcium antagonist or slow-channel inhibitor available as a sterile solution for intravenous injection in 5-mg (2 ml) ampules, 5-mg (2 ml) and 10-mg (4 ml) syringes, and 5-mg (2 ml) and 10-mg (4 ml) vials
Compared with the control given verapamil alone, the concurrent use of 1
The fu of (-)- (0
Utilizing a stereospecific high‐performance liquid chromatographic (HPLC) assay, the enantiomeric disposition of verapamil is reported after intravenous (1·0 mg kg−1) and oral (10 mg kg−1) administration of racemic verapamil to the rat model
v
2 After intravenous administration, plasma concentrations were much higher in the patient group such that the total Although the pharmacokinetics of verapamil in patients with renal impairment are not affected, caution should be exercised and careful patient monitoring is recommended
Methods We studied nine patients [ seven males, two females; median age 46 years (range, 31-57)] with Pharmacology Mechanism of Action
2
Blood pressure, heart rate and PR intervals were also measured at these times
After intravenous administration, the serum levels in all subjects declined bi-exponentially
Parker and Timothy J
2 After intravenous administration, plasma concentrations were much higher in the patient group such that the total plasma Objectives: The aim was to investigate the effect of Huang-Lian-Jie-Du-Decoction (HLJDD) on the pharmacokinetic behaviour of verapamil in rats
o
Following intravenous infusion in man, verapamil is eliminated bi-exponentially, with a rapid early distribution phase (half-life about 4 minutes) and a slower terminal elimination phase (half-life 2 to 5 hours)
IV: kinetic and dynamic effects after single intravenous and oral doses
Verapamil kinetics after intravenous and single and long‐term oral dosing were studied in patients with coronary Correlations between log plasma verapamil concentration and percentage increase in PR interval were greater after sublingual compared with oral dosing in all volunteers
Elizabeth Fahey-Mccarthy
5 mg/ml and sodium chloride 8
SummaryEtoposide is mainly metabolized by cytochrome P450 (CYP) 3A and is a substrate for P-glycoprotein (P-gp)
Absorption: Diltiazem is well absorbed from the GIT and undergoes extensive first-pass metabolism; resultant bioavailability is approximately 40%
Verapamil / pharmacokinetics* Verapamil / pharmacology* Substances Calcium Channel Disappearance kinetic characteristics of verapamil were determined in 9 patients after a single intravenous dose
The commonly used intravenous doses of 5-10 mg Verapamil produce transient, usually asymptomatic, reduction in normal systemic arterial pressure, systemic vascular
Class Calcium channel blocker Class IV antiarrhythmic Pharmacodynamics Blocks both activated and inactivated L-type calcium channels (alpha-1 subunit) Reduces
In the absence of heart disease, following a step by step increase of the dosage, the high plasma verapamil concentrations (617 to 2970 ng/mL) produce frequent but well
Clinical pharmacology study of drug interaction between fexofenadine hydrochloride and erythromycin: electrocardiographic findings and pharmacokinetics of
administration of the drugs
Plasma concentrations of verapamil and its metabolite, norverapamil, were measured after oral (10 mg/kg) or intravenous (1 mg/kg) administration
A single dose of etoposide was administered via oral (p
3 mg/kg) routes to rats alone (control animals) or together in combination with verapamil (2 or 6 mg/kg; experimental animals)
The pharmacology of verapamil
This study examined the effects of verapamil, a CYP3A and P-gp inhibitor, on the pharmacokinetics of etoposide in rats
; 3
The immediate-release diltiazem tablet has an onset of action of 30 to 60 minutes
Left ventricular dysfunction: Use with caution in left ventricular dysfunction; due to negative inotropic effects Anderson P, BondessoN U, Sylvén C
Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I
5 mg/kg of atorvastatin significantly increased the oral exposure of verapamil in rats
Thereupon, pharmacokinetic parameters were calculated using a two-compartment open model
Protein binding for the two isomers was also different
Aims: In an attempt to reverse multidrug resistance, in a recent trial of verapamil in association with doxorubicin, we used escalating doses of continuous intravenous (i
1080/00498254
DESCRIPTION
This study examined the effects of verapamil, a CYP3A and P-gp inhibitor, on the pharmacokinetics of etoposide in rats
; 3
Plasma concentrations of verapamil in DM rats, rats fed with H